NovaBay Pharmaceuticals (NBY) Announces $100M Stock Sale Agreement with Virtu Americas
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 20 2026
0mins
Source: seekingalpha
- Stock Price Plunge: NovaBay Pharmaceuticals saw its stock price drop approximately 54% on Tuesday following the announcement of a $100M stock sale agreement with Virtu Americas, indicating market concerns regarding this financing method.
- Sales Agreement Details: Under the agreement signed on January 20, NovaBay can sell its common stock at a par value of $0.01 per share, with Virtu acting as the sales agent, allowing for flexible fundraising opportunities for the company.
- Commission Structure: Virtu is entitled to a commission of up to 2.0% on any sales, meaning if $100M worth of stock is sold, Virtu could earn up to $2 million, potentially impacting NovaBay's net proceeds from the sales.
- Market Reaction: While this agreement provides funding support for NovaBay, heightened market concerns about the company's future direction have led analysts to maintain a “Hold” rating, reflecting caution regarding potential M&A risks.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
